Impact of renal function on mid-term outcomes in heart failure patients treated with tolvaptan.
Kensuke FujiokaSumio MizunoTaro IchiseTakao MatsuiHiroaki HiraseMasato YamaguchiTakahiko AoyamaMasakazu YamagishiNoboru FujinoMasa-Aki KawashiriKenshi HayashiPublished in: Therapeutic advances in cardiovascular disease (2019)
The continuous use of tolvaptan after discharge did not affect mid-term cardiac events of HF overall but may be associated with increased cardiac events in the subgroup with preserved renal function. These findings suggest that the tolvaptan administration might need to be limited to treatment of in-hospital acute HF.
Keyphrases
- acute heart failure
- heart failure
- left ventricular
- polycystic kidney disease
- liver failure
- healthcare
- cardiac resynchronization therapy
- drug induced
- atrial fibrillation
- randomized controlled trial
- acute care
- intensive care unit
- emergency department
- skeletal muscle
- combination therapy
- hepatitis b virus
- insulin resistance
- mechanical ventilation